Bio-IT World October 28, 2025
Kailera Therapeutics advances injectable dual GLP-1/GIP receptor agonist; Tubulis develops antibody-drug conjugate for ovarian cancer and lung adenocarcinomas; Trogenix advances their pipeline of potentially curative cancer therapies across multiple aggressive solid tumors into the clinic; and more.
$600M: Series B for Obesity Treatment
Kailera Therapeutics announced a $600 million Series B financing. The financing will be fully funded at closing and will support the advancement of Kailera’s leading obesity portfolio, including a global phase 3 clinical program of Kailera’s lead candidate KAI-9531, an injectable dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss. Kailera plans to initiate its global phase 3 program by year end. The program will include two trials in adults living with...
Today's Sponsors
Today's Sponsor